This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Domantis Limited. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Ruud De Wildt: Innovator in Inflammatory Disease Treatment
Introduction
Ruud De Wildt is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of medical science, particularly in the treatment of inflammatory diseases. His innovative work has led to the development of a patent that addresses chronic inflammatory conditions.
Latest Patents
Ruud De Wildt holds a patent titled "Antagonists against TNFR1 and methods of use therefor." This invention provides methods for treating inflammatory diseases by administering an antagonist of Tumor Necrosis Factor Receptor 1. The patent also includes ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds to Tumor Necrosis Factor Receptor 1. Additionally, it outlines methods for using these ligands, as well as nucleic acids encoding the ligands and recombinant host cells for their preparation.
Career Highlights
Ruud De Wildt is associated with Domantis Limited, a company that focuses on innovative therapeutic solutions. His work at Domantis has been instrumental in advancing research and development in the field of immunology. His expertise and dedication have contributed to the company's mission of providing effective treatments for various diseases.
Collaborations
Ruud has collaborated with notable colleagues, including Neil D Brewis and Benjamin P Woolven. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Ruud De Wildt's contributions to the field of inflammatory disease treatment through his innovative patent demonstrate his commitment to advancing medical science. His work continues to inspire future research and development in this critical area.